Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2026

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol. 2025 doi: 10.1002/art.43188 Epub ahead of print

Aymon R,

Salis Z,

Leeb BF,

Rotar Z,

Nina T,

Data from an international collaboration of registries show no evidence of an increase in CV events during the first 2 years of use with JAKi, compared to TNFi, in the general RA population.

Keywords:

June 2022

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumaticdrugs as used against rheumatoid arthritis in clinical practice

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab570

Huss V,

Bower H,

Wadström H,

Frisell T,

Askling J; ARTIS group

Observational, nationwide cohort study finds no increased risk for cancer overall in RA patients treated with TNFis, anti-CD20 or anti-IL6.

Publications

April 2026

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Keywords:

June 2022

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

Keywords:

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumaticdrugs as used against rheumatoid arthritis in clinical practice